Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.72B | 1.67B | 1.69B | 1.64B | 1.76B |
Gross Profit | 228.09M | 214.75M | 193.84M | 226.88M | 267.99M |
EBITDA | 73.96M | 75.21M | 62.94M | 77.88M | 144.83M |
Net Income | 39.47M | 38.39M | 34.24M | 48.54M | 98.68M |
Balance Sheet | |||||
Total Assets | 802.77M | 790.65M | 718.33M | 777.53M | 785.03M |
Cash, Cash Equivalents and Short-Term Investments | 107.31M | 147.46M | 121.48M | 185.19M | 264.34M |
Total Debt | 8.03M | 36.23M | 33.10M | 11.30M | 11.36M |
Total Liabilities | 302.85M | 334.04M | 292.16M | 324.85M | 304.57M |
Stockholders Equity | 499.93M | 456.62M | 426.17M | 452.68M | 480.46M |
Cash Flow | |||||
Free Cash Flow | 24.47M | 38.09M | -13.38M | 31.42M | 212.87M |
Operating Cash Flow | 30.80M | 43.50M | -8.17M | 37.11M | 217.21M |
Investing Cash Flow | 6.05M | -3.29M | 2.58M | -22.99M | -36.84M |
Financing Cash Flow | -31.05M | -12.15M | -38.93M | -82.65M | -68.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $1.49B | 13.89 | 11.19% | 2.61% | 19.16% | 31.92% | |
69 Neutral | $946.43M | 92.37 | 2.28% | ― | 5.17% | -65.33% | |
64 Neutral | $764.18M | 28.92 | 11.28% | ― | 30.04% | 43.47% | |
56 Neutral | $1.05B | ― | -10.01% | ― | -1.13% | -17.77% | |
51 Neutral | $7.35B | 0.50 | -65.61% | 2.47% | 15.28% | 1.44% | |
45 Neutral | $683.38M | 18.62 | -21.08% | ― | -18.13% | -215.78% | |
45 Neutral | $774.52M | 228.16 | 42.49% | ― | 9.05% | ― |
Healthcare Services Group, Inc. announced that Genesis HealthCare, Inc. filed for Chapter 11 bankruptcy on July 9, 2025. Despite this, HCSG expects to maintain its services to Genesis facilities without disruption. The bankruptcy will result in non-cash charges for HCSG in the second and third quarters of 2025. CEO Ted Wahl stated that while the Genesis situation is disappointing, the overall industry fundamentals remain strong, and HCSG’s growth and cash flow expectations for 2025 remain unchanged, with anticipated mid-single digit revenue growth and $60 to $75 million in cash flow from operations.
The most recent analyst rating on (HCSG) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Healthcare Services stock, see the HCSG Stock Forecast page.
On May 27, 2025, Healthcare Services held its annual shareholder meeting to vote on various management proposals. The shareholders elected nine directors for one-year terms, approved the executive compensation in a non-binding advisory vote, and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (HCSG) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Healthcare Services stock, see the HCSG Stock Forecast page.